National Clinical Research Center for Infectious Diseases, Guangdong Key Laboratory of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou, China.
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01368-19.
infection and nontuberculous mycobacteria (NTM) infections exhibit similar clinical symptoms; however, the therapies for these two types of infections are different. Therefore, the rapid and accurate identification of and NTM species is very important for the control of tuberculosis and NTM infections. In the present study, a Cas12a/guide RNA (gRNA)-based platform was developed to identify and most NTM species. By designing species-specific gRNA probes targeting the sequence, a Cas12a/gRNA-based platform successfully identified and six major NTM species (, , , , , and ) without cross-reactivity. In a blind assessment, a total of 72 out of 73 clinical isolates were correctly identified, which is consistent with previous sequencing results. These results suggest that the Cas12a/gRNA-based platform is a promising tool for the rapid, accurate, and cost-effective identification of both and NTM species.
感染和非结核分枝杆菌（NTM）感染表现出相似的临床症状；然而，这两种类型的感染的治疗方法是不同的。因此，快速准确地鉴定结核分枝杆菌和 NTM 物种对于控制结核病和 NTM 感染非常重要。在本研究中，开发了一种 Cas12a/guide RNA（gRNA）为基础的平台来鉴定结核分枝杆菌和大多数 NTM 物种。通过设计针对 序列的物种特异性 gRNA 探针，Cas12a/gRNA 为基础的平台成功地鉴定了结核分枝杆菌和六种主要的 NTM 物种（结核分枝杆菌、牛分枝杆菌、非洲分枝杆菌、堪萨斯分枝杆菌、海分枝杆菌和龟分枝杆菌），没有交叉反应。在一项盲法评估中，总共 73 株临床分离株中有 72 株得到了正确鉴定，这与之前的 测序结果一致。这些结果表明，Cas12a/gRNA 为基础的平台是一种快速、准确和具有成本效益的鉴定结核分枝杆菌和 NTM 物种的有前途的工具。
